Search results for "Androgen"

showing 10 items of 326 documents

Long-term outcome of antiandrogen monotherapy in advanced prostate carcinoma: 12-year results of a phase II study

2003

OBJECTIVE To present the long-term outcome of patients with locally advanced or metastatic prostate carcinoma treated by first-line antiandrogen monotherapy. PATIENTS AND METHODS From 1983 to 1990, 41 patients with advanced prostate carcinoma were treated with flutamide monotherapy until progression or the appearance of toxicity. Twenty-five patients (61%) had T3-T4N0M0 and 16 (39%) T2–4N0–3M1 prostate carcinoma. Consensus criteria were adopted to evaluate the response. Plasma testosterone and sexual function were recorded for the first 3 years. RESULTS Flutamide was administered for up to 147 months; seven patients (17%) interrupted the treatment because of toxicity. There was an objective…

medicine.medical_specialtyPerformance statusmedicine.drug_classbusiness.industryUrologyUrologyAntiandrogenmedicine.diseaseSurgeryFlutamideProstate-specific antigenchemistry.chemical_compoundProstate cancerchemistrymedicineCarcinomaHormonal therapymedicine.symptomBone painbusinessBJU International
researchProduct

Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis.

2011

Objective To quantify the magnitude and pattern of low-density lipoprotein (LDL) cholesterol and nonhigh-density lipoprotein (HDL) cholesterol levels in women with polycystic ovary syndrome (PCOS) versus control women. Design Systematic review and meta-analysis of lipid levels in published cross-sectional studies worldwide where PCOS women and controls were examined and sampled. Main Outcome Measure(s) Differences in plasma lipids (including triglycerides, HDL-cholesterol, LDL-cholesterol, and nonHDL-cholesterol) in PCOS versus control subjects were calculated. Comparisons were made with and without body mass index (BMI) matching. Result(s) Triglyceride levels were 26 mg/dL (95% confidence …

medicine.medical_specialtySettore MED/13 - EndocrinologiaBody Mass Indexchemistry.chemical_compoundRisk FactorsMedicineHumansDyslipidemiasGynecologyTriglyceridebusiness.industryCholesterolHyperandrogenismnutritional and metabolic diseasesObstetrics and Gynecologymedicine.diseasePolycystic ovaryLipidsConfidence intervalReproductive MedicinechemistryPolycystic Ovary Syndrome dyslipidemia cardiovascular risklipids (amino acids peptides and proteins)FemalebusinessHyperandrogenismBody mass indexDyslipidemiaLipoproteinPolycystic Ovary SyndromeFertility and sterility
researchProduct

Determination of Nuclear Prostatic Androgen Receptors by FPLC (Fast Protein Liquid Chromatography)

1987

The experimental detection of steroid receptors, quantitative as well as qualitative, has been received with wide-spread interest in the research of the various effects of steroid hormones during recent years. The quantitative measurement of cyto- and karyoplasmatic prostatic androgen receptors, carried out through such methods as the Dextran-Coated-Charcoal-Method (DCC) (Snochowsky et al. 1977), the gradient centrifugation method (Mainwaring and Milroy 1975; Menon et al. 1978) or the Hydroxyl-apatite process (Murthy et al. 1984; Pavlik and Coulson 1976), represent unprecise or complicated analytical processes, which are due to technical factors, such as proteolytical degradation, the time …

medicine.medical_specialtyTemperature sensitivitybusiness.industrymedicine.medical_treatmentEstrogen receptorFast protein liquid chromatographymedicine.diseaseSteroidAndrogen receptorBreast cancerEndocrinologyInternal medicinemedicineCancer researchReceptorbusinessHormone
researchProduct

Hormonal adaptations and modelled responses in elite weightlifters during 6 weeks of training.

1992

The concentrations of serum testosterone, sex-hormone-binding-globulin (SHBG) and luteinizing hormone (LH) were examined throughout 1-year of training in six elite weightlifters. A systems model, providing an estimation of fatigue and fitness, was applied to records of training volume and performance levels in clean and jerk. The analysis focused on a 6-week training period during which blood samples were taken at 2-week intervals. A 4-week period of intensive training (period I) could be distinguished from the following 2-week period of reduced training (period II). During period I, decreases in serum testosterone (P less than 0.05) and increases in serum LH concentrations (P less than 0.0…

medicine.medical_specialtyTime FactorsWeight LiftingPhysiologymedicine.drug_classStrength trainingPhysical fitnessSex hormone-binding globulinPhysiology (medical)Internal medicineSex Hormone-Binding GlobulinmedicineHumansOrthopedics and Sports MedicineTestosteroneTestosteronebiologybusiness.industryPublic Health Environmental and Occupational HealthGeneral MedicineLuteinizing HormoneAndrogenEndocrinologyPhysical Fitnessbiology.proteinGonadotropinbusinessLuteinizing hormoneHormoneEuropean journal of applied physiology and occupational physiology
researchProduct

The effects of transdermal testosterone and oestrogen therapy on dry eye in postmenopausal women: a randomised, placebo-controlled, pilot study

2016

Aims Sex hormones could provide a future treatment avenue for dry eye post menopause. However, there are few well-controlled studies. This study investigates the impact of testosterone and oestrogen on dry eye symptoms and signs in postmenopausal women. Methods A randomised double-blind placebo-controlled pilot study was conducted involving 40 women with dry eye (age 63.9±5.1 years, 13.2±6.3 years post menopause). Ten women were assigned to each of four treatment groups: transdermal testosterone, oestradiol, testosterone/oestradiol combination and placebo. Assessment at baseline and after 8 weeks: ocular symptoms, tear osmolarity, tear stability, tear secretion, meibomian gland assessment, …

medicine.medical_specialtyTime Factorsmedicine.drug_classMeibomian glandPhysiologyPilot ProjectsAdministration CutaneousPlacebo03 medical and health sciencesCellular and Molecular Neurosciencechemistry.chemical_compound0302 clinical medicineDehydroepiandrosterone sulfateDouble-Blind MethodInternal medicineHumansMedicineTestosteroneTear secretionRetrospective Studies030219 obstetrics & reproductive medicinebusiness.industryMeibomian GlandsEstrogensTestosterone (patch)Middle AgedAndrogeneye diseasesSensory SystemsPostmenopauseOphthalmologyTreatment Outcomemedicine.anatomical_structureEndocrinologychemistryTearsAndrogens030221 ophthalmology & optometryTearsDry Eye SyndromesFemalesense organsbusinessFollow-Up StudiesHormoneBritish Journal of Ophthalmology
researchProduct

Predictive factors of polycystic ovary syndrome in girls with precocious pubarche

2021

Objective: The aim of this study is to clarify, in girls with premature pubarche (PP), the influence of premature androgenization on the prevalence of polycystic ovary syndrome (PCOS). Design and patients: Ninety-nine PP girls, 63 who developed PCOS and 36 who did not develop PCOS, were retrospectively included. Clinical, anthropometric, and metabolic parameters were evaluated at the time of diagnosis of PP and after 10 years from menarche to find predictive factors of PCOS. Results: Young females with PP showed a PCOS prevalence of 64% and showed a higher prevalence of familial history of diabetes (P = 0.004) and a lower prevalence of underweight (P = 0.025) than PP-NO-PCOS. In addition, g…

medicine.medical_specialtyWaistendocrine system diseasesEndocrinology Diabetes and MetabolismDiseases of the endocrine glands. Clinical endocrinologySettore MED/13 - EndocrinologiahyperandrogenismEndocrinologyInsulin resistanceInternal medicineDiabetes mellitusinsulin resistanceInternal MedicinemedicineHyperandrogenism .insulin resistancebusiness.industryResearchHyperandrogenismdyslipidemianutritional and metabolic diseasesvisceral obesitymedicine.diseaseRC648-665Polycystic ovaryEndocrinologyMenarcheUnderweightmedicine.symptomprecocious menarchebusinessDyslipidemiaEndocrine Connections
researchProduct

Molecular Analysis of the Androgen Receptor Gene in 52 Patients with Complete or Partial Androgen Insensitivity Syndrome: A Collaborative Study

1992

In patients with androgen insensitivity syndrome (AIS), RFLP study of the androgen receptor gene made it possible to analyze whether deletions or mutations could be responsible for abnormalities in androgen responsiveness. We studied RFLPs of DNA from 25 46,XY patients with partial AIS (PAIS), defined as a concentration of androgen receptor in genital-skin fibroblasts less than 340 fmol/mg DNA, and DNA from 27 46,XY patients with complete AIS (CAIS) with no detectable androgen receptor site. DNA samples were digested with BamHI, EcoRI, HindIII and TaqI restriction enzymes and hybridized with three cDNA probes covering the three domains of the androgen receptor. When we had the maternal and …

medicine.medical_specialtyX Chromosomemedicine.drug_classEndocrinology Diabetes and MetabolismMolecular Sequence DataDeoxyribonuclease HindIIIBiologyurologic and male genital diseasesPolymerase Chain Reactionchemistry.chemical_compoundEndocrinologyInternal medicinemedicineHumansPartial androgen insensitivity syndromeGeneSex Chromosome AberrationsBase SequenceAndrogen Receptor GeneDNASyndromeMetribolonemedicine.diseaseAndrogenMolecular analysisEndocrinologychemistryReceptors AndrogenMutationAndrogensAndrogen insensitivity syndromeRestriction fragment length polymorphismPolymorphism Restriction Fragment LengthDNAHormone Research
researchProduct

Darstellung und Reaktionen von 2-Methylen-canrenon

1995

Ausgehend vom Mannich-Salz 1 des Aldosteronantagonisten Canrenon oder von 2-Methylen-canrenon (2) wurden die am A-Ring anellierten Hetero- und Carbocyclen 5, 6, 8–13 dargestellt. Mit den Verbindungen 2, 3, 4b, 5, 6b, 8 und 12 wurden Bindungsstudien am Estradiol-, Progesteron-, Androgen-, Glucocorticoid- und Mineralocorticoid-Rezeptor sowie an den Serumproteinen Sexualhormonbindendes Globulin (SHBG) und Corticosteroidbindendes Globulin (CBG) durchgefuhrt. Die relativen Bindungsaffinitaten lagen bei CBG unter 1%, in allen anderen Fallen niedriger als 0.01%. Synthesis and Reactions of 2-Methylene-canrenone Starting from the Mannich salt 1 of the aldosterone antagonist canrenone or from 2-methy…

medicine.medical_specialtybiologyGlobulinChemistrymedicine.drug_classStereochemistrymedicine.medical_treatmentPharmaceutical ScienceAndrogenBlood proteinsSteroidSex hormone-binding globulinEndocrinologyMineralocorticoidInternal medicineDrug Discoverymedicinebiology.proteinCanrenonehormones hormone substitutes and hormone antagonistsGlucocorticoidmedicine.drugArchiv der Pharmazie
researchProduct

Product of aromatase activity in intact LNCaP and MCF-7 human cancer cells

1997

We investigated conversion rates of androgens to estrogens in cultured, hormone-responsive prostate (LNCaP) and breast (MCF-7) human cancer cells. For this purpose, we adopted an intact cell analysis, whereby cells were incubated for different incubation times in the presence of close-to-physiological (1 nM) or supraphysiological (1 μM) concentrations of labelled androgen precursors, i.e. testosterone (T) and androstenedione (Δ4Ad). The aromatase activity, as measured by estrogen formation, was detected in LNCaP cells (0.5 pmol/ml), even though to a significantly lower extent than in MCF-7 cells (5.4 pmol/ml), using 1 μM T after 72 h incubation. Surprisingly, LNCaP cells displayed a much hi…

medicine.medical_specialtybiologymedicine.drug_classEndocrinology Diabetes and MetabolismClinical BiochemistryCell Biologyurologic and male genital diseasesAndrogenBiochemistryIn vitroEndocrinologyEndocrinologyMCF-7Cell cultureInternal medicineLNCaPmedicinebiology.proteinMolecular MedicineAndrostenedioneAromataseMolecular BiologyTestosteroneThe Journal of Steroid Biochemistry and Molecular Biology
researchProduct

Fat Distribution and Adipose Products in Polycystic Ovary Syndrome

2007

Because adipose tissue is a complex endocrine organ that secretes many substances with profound effects on metabolism and the cardiovascular (CV) system, most obese subjects have an increased CV risk. However, 20% of obese subjects are metabolically healthy, and many studies suggest that fat distribution, in particular abdominal fat excess, is the most important factor that determines a secretion of adipose products that may increase CV risk.

medicine.medical_specialtybusiness.industryHyperandrogenismAdipose tissueFat distributionmedicine.diseasePolycystic ovaryEndocrinologyInternal medicinemedicineAbdominal fatEndocrine systemSecretionObese subjectsbusiness
researchProduct